Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

An ambulatory care physician conducts a telehealth consultation with a 65-year-old female patient reporting a 48-hour history of spontaneous epistaxis and multiple large bruises on her extremities. Her medical history is notable for nonvalvular atrial fibrillation. To prevent thromboembolism, she has taken rivaroxaban daily for three years without hemorrhagic events. Four days prior to this consultation, she visited an urgent care center for acute bronchitis and was given a prescription for a 10-day course of clarithromycin. The patient denies experiencing headaches, visual disturbances, motor weakness, or dark stools. Vital signs are within normal limits. Which of the following is the most appropriate next step in the patient's management?

  1. Advise the patient to stop taking both clarithromycin and rivaroxaban immediatelyCevap
  2. B
    Prescribe oral vitamin K to reverse the current anticoagulant effect
  3. C
    Change the anticoagulant from rivaroxaban to apixaban while completing the antibiotic course
  4. D
    Direct the patient to the emergency department for an immediate non-contrast head computed tomography scan
  5. E
    Recommend over-the-counter ibuprofen for discomfort associated with the ecchymoses and continue current medications

Cevap

Advise the patient to stop taking both clarithromycin and rivaroxaban immediately.
The correct response addresses a significant drug-drug interaction. Rivaroxaban is a direct Factor Xa inhibitor that is metabolized by the hepatic cytochrome P450 3A4 (CYP3A4) enzyme and transported by P-glycoprotein (P-gp). Clarithromycin is a potent inhibitor of both CYP3A4 and P-gp. When taken concurrently, clarithromycin drastically decreases the clearance of rivaroxaban, leading to supratherapeutic anticoagulant levels and subsequent bleeding manifestations such as epistaxis and ecchymoses. In a hemodynamically stable patient without life-threatening bleeding, the most appropriate next step in treatment evaluation and management is to hold both the offending interacting drug (clarithromycin) and the anticoagulant until the bleeding ceases and the medications are cleared from the system.

Adım Adım Çözüm

1
Evaluate the patient's presentation and recent medication changes.
The patient developed spontaneous bleeding shortly after clarithromycin was added to her chronic rivaroxaban therapy.
Identifying recent additions to a medication regimen is essential for diagnosing adverse drug events.
2
Analyze the pharmacokinetic properties of the involved medications.
Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein. Rivaroxaban is a substrate for both.
Understanding metabolic pathways highlights that clarithromycin significantly increases rivaroxaban serum concentrations, elevating bleeding risk.
3
Determine the appropriate clinical intervention based on bleeding severity.
The patient has mild to moderate bleeding (epistaxis, ecchymoses) without hemodynamic instability or neurological symptoms.
For mild bleeding secondary to a drug interaction, the standard of care is discontinuing the interacting medications and monitoring, rather than administering reversal agents or ordering emergent imaging.

Anahtar Kavram

Monitoring and Treatment Evaluation for DOACs and CYP3A4 interactions
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru